Impact of Cerebral Small Vessel Disease on Functional Decline: Bleeding With Antithrombotic Therapy 2 Study
Stroke · 2026-07 · 57 (7) · 2065-2075
DOI: 10.1161/strokeaha.125.054738 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Stroke, 2026-07. Verfasst von Yoshito Arakaki und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.A., K.M., M.K., S.Y., K. Tanaka, M. Shiozawa, K.…. Hauptthemen laut MEDLINE: Cerebral Small Vessel Diseases, Fibrinolytic Agents, Hemorrhage. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: To what extent cerebral small vessel disease (SVD) contributes to functional disability remains unclear. We investigated the longitudinal effect of SVD burden on functional decline. METHODS: In this investigator-initiated, prospective, multicenter, and observational study, patients receiving oral antithrombotic therapy for cerebrovascular or cardiovascular diseases were enrolled from 52 hospitals across Japan (2016–2019) and followed for 24 months. SVD score (range, 0–4) was calculated on baseline magnetic resonance imaging obtained under prespecified conditions. The outcomes were an increase in modified Rankin Scale (mRS) score from baseline to end of follow-up (ΔmRS score ≥1). Logistic regression evaluated the association between ΔmRS score ≥1 and SVD score, adjusting for age, sex, premorbid mRS, vascular risk factors, antithrombotic therapy, magnetic resonance imaging field strength, and bleeding or ischemic events during follow-up. Bleeding and ischemic events were treated as time-dependent covariates. Causal mediation analyses using a 4-way decomposition separated the effects of SVD score ≥3 on ΔmRS score ≥1 into direct and indirect effects (mediated by major bleeding or ischemic events). RESULTS: Of 5378 patients enrolled, 613 were excluded mainly due to the lack of clinical or imaging data. Finally, 4765 patients were analyzed (1573 women; median age, 73 years); ΔmRS score ≥1 was observed in 13.2% of patients with SVD score 0, 16.1% with 1, 20.7% with 2, 28.1% with 3, and 28.2% with 4. SVD score of 3 (adjusted odds ratio, 1.65 [95% CI, 1.27–2.15]) and SVD score of 4 (1.62 [95% CI, 1.19–2.19]) were associated with ΔmRS score ≥1 compared with SVD score of 0. Causal mediation analysis indicated that 73.05% of the total effect of SVD score ≥3 on ΔmRS score ≥1 was attributed to the controlled direct effect (coefficient, 0.497 [95% CI, 0.26–0.73]). CONCLUSIONS: SVD burden was associated with functional decline beyond significant bleeding or ischemic events.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan (Y.A., K.M., M.K., S.Y., K. Tanaka, M. Shiozawa, K. Toyoda).
- Department of Neurology, Keio University, School of Medicine, Tokyo, Japan (Y.A., J.N., K. Toyoda).
- Division of Neurology, Department of Internal Medicine, Saga University Faculty of Medicine, Japan (Y.Y.).
- Department of Neurology, Kansai Medical University, Hirakata, Japan (Y.Y.).
- Institute for Biomedical Sciences, Iwate Medical University, Yahaba, Japan (M. Sasaki).
- Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan (S.F.).
ORCID-Profile: Yoshito Arakaki, Kaori Miwa, Masatoshi Koga, Sohei Yoshimura, Kanta Tanaka, Jin Nakahara, Makoto Sasaki, Shigeru Fujimoto, Masayuki Shiozawa, Toru Iwama, Masafumi Ihara, Teruyuki Hirano, Kazunori Toyoda
Zitieren
APA
Arakaki, Y., Miwa, K., Koga, M., Yoshimura, S., Tanaka, K., Nakahara, J., Yakushiji, Y., Sasaki, M., Fujimoto, S., Shiozawa, M., Okuda, S., Iwama, T., Ihara, M., Nishiyama, K., Hirano, T., Toyoda, K., & for BAT2 Investigators (2026). Impact of Cerebral Small Vessel Disease on Functional Decline: Bleeding With Antithrombotic Therapy 2 Study. Stroke, 57(7), 2065-2075. https://doi.org/10.1161/strokeaha.125.054738
Vancouver
Arakaki Y, Miwa K, Koga M, Yoshimura S, Tanaka K, Nakahara J, et al. Impact of Cerebral Small Vessel Disease on Functional Decline: Bleeding With Antithrombotic Therapy 2 Study. Stroke. 2026;57(7):2065-2075. doi:10.1161/strokeaha.125.054738
BibTeX
@article{Arakaki2026,
author = {Arakaki, Yoshito and Miwa, Kaori and Koga, Masatoshi and Yoshimura, Sohei and Tanaka, Kanta and Nakahara, Jin and Yakushiji, Yusuke and Sasaki, Makoto and Fujimoto, Shigeru and Shiozawa, Masayuki and Okuda, Satoshi and Iwama, Toru and Ihara, Masafumi and Nishiyama, Kazutoshi and Hirano, Teruyuki and Toyoda, Kazunori and for BAT2 Investigators, for BAT2 Investigators},
title = {Impact of Cerebral Small Vessel Disease on Functional Decline: Bleeding With Antithrombotic Therapy 2 Study},
journal = {Stroke},
year = {2026},
volume = {57},
number = {7},
pages = {2065--2075},
doi = {10.1161/strokeaha.125.054738}
}
EUVIMED